Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

61. Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis

Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis RESEARCH Open Access Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis Teresa Schleker 1 , Eva-Maria Jacobsen 1 , Benjamin Mayer 2 , Gudrun Strauss 1 , Klaus-Michael Debatin 1 and Carsten Posovszky 1,3* Abstract Background: Children (...) with inflammatory bowel disease (IBD) or autoimmune hepatitis (AIH) are at risk for severe infections. This is partially a result of their chronic disease condition but, moreover, a side effect of their immunosuppressive therapy. Currently, vaccinations with live vaccines are regarded as contraindicated under immunosuppressive therapy, mainly because of concerns about side effects and a lack of data showing an adequate immune reaction. As there is no systematic study on the individual immunoreactivity under immunosuppressive

Molecular and cellular pediatrics2018 Full Text: Link to full Text with Trip Pro

62. Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis Acute Decompensation Boosts Hepatic Collagen Type III Deposition and Deteriorates Experimental and Human Cirrhosis Michael Praktiknjo, 1* Jennifer Lehmann, 1* Mette J. Nielsen, 2,3* Robert Schierwagen, 1 Frank E. Uschner, 1 Carsten Meyer, 4 Daniel Thomas, 4 Christian P. Strassburg, 1 Flemming Bendtsen, 5 Søren Møller , 6 Aleksander Krag, 3 Morten A. Karsdal, 2 Diana J. Leeming, 2 (...) ** and Jonel Trebicka 1,3,7,8** Patients with end-stage liver disease develop acute decompensation (AD) episodes, which become more frequent and might develop into acute-on-chronic liver failure (ACLF). However, it remains unknown how AD induces acceleration of liver disease. We hypothesized that remodeling of collagen type III plays a role in the acceleration of liver cirrhosis after AD and analyzed its formation (Pro-C3) and degradation (matrix metalloproteinase-degraded type III collagen [C3M]) markers

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

63. Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series Case Report RibavirininAcuteHepatitisEInfectioninPatientswith GynecologicalCancer:ACaseSeries Dominik Bettinger # * 1,2 , Stefan Schlabe #3,4 , Sven Pischke 5 , Michael R. Mallmann 7 , Mignon-Denise Keyver-Paik 4,6 , Walther Kuhn 4,6 , Christian P. Strassburg 3,4 , Robert Thimme ‡1 and Ulrich Spengler ‡3,4 1 DepartmentofMedicineII,MedicalCenterUniversityofFreiburg,FacultyofMedicine,UniversityofFreiburg (...) ,Freiburg,Germany; 2 Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 3 Department of Internal MedicineI,UniversityofBonn,Bonn,Germany; 4 CenterforIntegratedOncologyCologne/Bonn,Bonn,Germany; 5 Departmentof Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6 Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany; 7 Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany Abstract Hepatitis E

Journal of clinical and translational hepatology2018 Full Text: Link to full Text with Trip Pro

64. A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 ANewMechanismofActionofGlucagon- LikePeptide-1AgonistinHepaticSteatosis: PromotionofHepaticInsulinClearance ThroughInductionofCarcinoembryonic Antigen-RelatedCellAdhesionMolecule1 SEE ARTICLE ON PAGE 35 N onalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases (...) in industrialized countries, with approximately 30%-40% of adults suffering from NAFLD. Of those, 15%-20% will develop to its progressive entity nonal- coholic steatohepatitis (NASH), a condition that may further progress to liver ?brosis and cirrhosis. (1) Because insulin resistance and visceral obesity are major contributors in the pathogenesis of NAFLD/ NASH, weight loss, exercise, and insulin-sensitizing drugs are considered as primary treatment regimens. Obeticholic acid, a farnesoid X nuclear receptor ago

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

65. Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study

Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study Original Article SustainedResponsesinChronicHepatitisBPatientswith Nucleos(t)ideAnalogueDrug-resistanceafterPeg-interferon Alfa-2aAdd-onTreatment:ALong-termCohortStudy Yunhua Liu*, Weikun Li, Ting Jia, Dan Peng, Huimin Li, Xiaofei Li and Songqin Lv The Third People’s Hospital of Kunming City, Kunming, China Abstract (...) BackgroundandAims: The use of additional nucleos(t)ide analogues (NAs) without cross-resistance to previously used NAs as a rescue therapy is recommended by most interna- tional guidelines for chronic hepatitis B patients with NA- resistance. We aimed to investigate the efficacy and safety of combination therapy of peg-interferon (PegIFN) alfa-2a and NA in these patients, comparing to those who switch to an alternative NA therapy without cross-resistance. Methods:Inthisprospective,comparativeandcohortstudy

Journal of clinical and translational hepatology2018 Full Text: Link to full Text with Trip Pro

66. Hepatitis E virus replication and interferon responses in human placental cells

Hepatitis E virus replication and interferon responses in human placental cells Hepatitis E Virus Replication and Interferon Responses in Human Placental Cells Leonard Knegendorf, 1* Svenja A. Drave, 1* Viet Loan Dao Thi, 2 Yannick Debing, 3 Richard J. P. Brown, 1 Florian W. R. Vondran , 4,5 Kathrin Resner, 1 Martina Friesland, 1 Tanvi Khera, 1 Michael Engelmann, 1 Birgit Bremer, 6 Heiner Wedemeyer, 5,6 Patrick Behrendt, 1,5,6 Johan Neyts, 3 Thomas Pietschmann, 1,5 Daniel Todt , 1 and Eike (...) Steinmann 1 Hepatitis E virus (HEV) is a member of the genus Orthohepevirus in the family Hepeviridae and the causative agent of hepa- titis E in humans. HEV is a major health problem in developing countries, causing mortality rates up to 25% in pregnant women. However, these cases are mainly reported for HEV genotype (gt)1, while gt3 infections are usually associated with subclinical courses of disease. The pathogenic mechanisms of adverse maternal and fetal outcome during pregnancy in HEV-infected

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

67. Autoimmune hepatitis

Autoimmune hepatitis Autoimmune hepatitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Autoimmune hepatitis Last reviewed: August 2018 Last updated: March 2018 Summary More frequently affects women and has a variable course with different clinical manifestations, ranging from no symptoms to fulminant hepatic failure. Concurrent autoimmune diseases are often present. Aminotransferase levels are usually more (...) strikingly raised than bilirubin and gamma-GT levels. Characterised by the presence of circulating auto-antibodies (ANA, smooth muscle antibody, perinuclear anti-neutrophil cytoplasmic auto-antibody, anti-soluble liver antigen/liver pancreas, anti-liver kidney microsomal-1, anti-liver cytosol) with a high serum globulin concentration and inflammatory changes on liver histology. Treatment options include corticosteroids alone or in combination with other immunosuppressants. Liver transplantation is

BMJ Best Practice2018

68. Hepatitis C

Hepatitis C Hepatitis C - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis C Last reviewed: August 2018 Last updated: June 2018 Summary Transmission is through percutaneous exposure to infected blood, most commonly through injection of illicit drugs or transfusion of contaminated blood products in developed countries, or via contaminated medical or dental equipment in resource-poor countries. Following acute (...) exposure to hepatitis C virus, about 55% to 85% of patients develop chronic hepatitis C. Most infections are asymptomatic; however, hepatic inflammation is often present and can lead to progressive hepatic fibrosis. The goal of treatment is to eradicate the virus, achieve a sustained virological response, and prevent disease progression. Oral direct-acting antiviral therapies are standard treatment; therapy is evolving at a rapid pace. Long-term complications of chronic infection include cirrhosis

BMJ Best Practice2018

69. Hepatitis B

Hepatitis B Hepatitis B - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis B Last reviewed: August 2018 Last updated: April 2018 Summary Most people are asymptomatic, although some will present with complications such as cirrhosis, hepatocellular carcinoma, or liver failure. People from endemic areas (Asia, Africa), or injection drug users and those with high-risk sexual behaviours, are at an increased risk (...) for infection. Serological markers are essential in making the diagnosis and evaluating disease activity, including differentiating between people with acute and chronic infection and chronic asymptomatic carriers. Therapy for acute infection is almost always supportive care alone. However, some patients with acute infection may develop liver failure, and these patients may require referral to a liver transplant centre. Therapy for chronic infection includes nucleoside/nucleotide analogues and pegylated

BMJ Best Practice2018

70. Hepatitis A

Hepatitis A Hepatitis A - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis A Last reviewed: August 2018 Last updated: March 2018 Summary Transmission of Hepatits A usually precedes symptoms by 2 weeks when stool concentrations are highest. Patients are considered non-infectious 1 week after onset of jaundice. Symptomatic patients may present with abrupt-onset fever, abdominal pain, malaise, and jaundice. IgM (...) anti-hepatitis A virus serology is the test of choice for diagnosis. Common examination findings are hepatomegaly and clinical jaundice with marked elevation of serum transaminases (usually >1000 units/L). No specific therapy is available and treatment is supportive. Post-exposure prophylaxis may be with active or passive immunisation, depending on specific patient factors, and according to individual national guidelines. Definition Hepatitis A virus (HAV) is an RNA virus. It is not associated

BMJ Best Practice2018

73. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma

Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma 29091283 2017 11 27 2017 11 28 1365-2168 104 13 2017 Dec The British journal of surgery Br J Surg Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. 1775-1784 10.1002/bjs.10677 Hepatic resection and radiofrequency ablation (RFA) are treatment options for early-stage hepatocellular carcinoma (HCC). Whether (...) tumour recurrence and long-term survival favour either treatment has not been established. This randomized trial aimed to test the hypothesis that RFA is superior to hepatic resection in terms of lower tumour recurrence rate and better long-term survival. Patients with early-stage HCC (solitary tumour no larger than 5 cm; or no more than 3 tumours, each 3 cm or smaller) were randomized into hepatic resection and RFA groups. Demographic and clinical characteristics, and short- and long-term outcome

EvidenceUpdates2018

75. Serum Vitamin D Levels in Treatment-naïve Chronic Hepatitis B Patients

Serum Vitamin D Levels in Treatment-naïve Chronic Hepatitis B Patients JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / OCT-DEC 2017 / VOL 5 | ISSUE 4 230 Address for Correspondence: Dr. Mohamed Hassany, Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute (NHTMRI), P .O. 11441, 10 Kasr Al Aini Street, Cairo, Egypt Email: mohamadhassany@yahoo.com Access this article online Website: www.intern-med.com DOI: 10.1515/jtim-2017-0038 Quick Response Code: Original (...) Article ABSTRACT Background and Objectives: According to the demographic health survey conducted in 2015, Egypt had 10% documented prevalence of anti-HBc positive patients aged 1-59 and 1% viremic patients amongst the population in the same age group, with a domination of genotype D. Several studies claimed the possible role of vitamin D deficiency in hepatitis B virus (HBV) replication and disease progression. Patients and Methods: Serum vitamin D levels [25(OH) D3] were assessed in 96 HBeAg negative

Journal of translational internal medicine2017 Full Text: Link to full Text with Trip Pro

76. Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012.

Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012. Background: Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2030. Objective: To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV patients"). Design: Nationally (...) representative cross-sectional survey. Setting: United States. Participants: 18 089 adults receiving HIV medical care who participated in the Medical Monitoring Project during 2009 to 2012. Measurements: Primary outcomes were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immunity or infection (candidates to initiate vaccination), and 2) initiation of vaccination among candidates, defined as documentation of at least 1 vaccine dose in a 1-year surveillance period

Annals of Internal Medicine2017

77. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review

Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review 29607308 2018 11 14 2225-0719 6 1 2018 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. 79-84 10.14218/JCTH.2017.00067 Hepatocellular carcinoma (HCC) is a leading cause of liver-related death worldwide. Hepatitis C virus (HCV) infection is a major cause of advanced hepatic fibrosis and cirrhosis, with significantly increased risk (...) Hepatology. 2014 Dec;60(6):1871-8 25065513 Clin Exp Hepatol. 2017 Jun;3(2):47-55 28856290 J Viral Hepat. 2017 Nov;24(11):976-981 28504854 J Hepatol. 2016 Oct;65(4):859-860 27392425 Gastroenterology. 2006 Mar;130(3):703-14 16530512 Gastroenterology. 2017 Mar;152(4):911-912 28161225 Am J Gastroenterol. 2014 Apr;109(4):542-53 24513805 J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):456-62 25559606 Recent Results Cancer Res. 2013;190:33-55 22941012 Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1261-8

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

78. Alcoholic Hepatitis: Lost in Translation

Alcoholic Hepatitis: Lost in Translation Review Article AlcoholicHepatitis:LostinTranslation Benjamin L. Woolbright* and Hartmut Jaeschke Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA Abstract Alcoholic hepatitis is the most severe and acute form of alco- holic liver disease. The mortality rate associated with alcoholic hepatitis is high, largely due to the lack of suitable pharmaco (...) - logicalinterventions.Whiletherehasbeensubstantialresearch inthearea,generatingpharmacologicalinterventionshasbeen plagued by the lack of a robust mouse model both for testing and for understanding the underlying pathology. A number of majornotable advances have been made in this area recently, with the goal of generating a mouse model of alcoholic hepatitis. The purpose of this article is to review recent advancesinmodelingalcoholicliverdiseasebothinvitroandin vivointhemouse,andplacetheminthecontextofthegreater spectrumofalcoholicliverdisease

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

79. Correction to: Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection

Correction to: Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection CORRECTION Correction to: Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection Ebrahim Eskandari 1,2 • Tayebeh Dahmardeh 3 • Fatemeh Dahmardeh 4 • Elham Pahlevani 5 • Malihe Metanat 5 Published online: 8 December 2017 Indian Virological Society 2017 Correction to: VirusDis. (July–September 2017) 28(3

Virusdisease2017 Full Text: Link to full Text with Trip Pro

80. Autoimmune Hepatitis in the Asia-Pacific Area

Autoimmune Hepatitis in the Asia-Pacific Area Review Article AutoimmuneHepatitisintheAsia-PacificArea Qi-Xia Wang # ,LiYan # and Xiong Ma* Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China Abstract Autoimmune hepatitis has been considered as a relatively (...) of autoimmune hepatitis, mainly focusing on the epidemiologyandgenetics,personalizeddiagnostics,individ- ualized treatment strategies, special subgroups and out- comes. Most of the research in the literature is based on Japanese and Chinese populations. Citationofthisarticle:WangQX,YanL,MaX.Autoimmune hepatitis in the Asia-Pacific area. J Clin Transl Hepatol 2018;6(1):1–9. doi: 10.14218/JCTH.2017.00032. Introduction Autoimmune hepatitis (AIH) was first reported in the early 1950s by the Swedish physician

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro